Natural Gas Stocks Investor Alert: Progress Energy (TSX:PRQ) Spike over 70% on PETRONAS Deal

New York, NY - June 28, 2012 (Investorideas.com Newswire, www.naturalgasstocks.com) Investorideas.com, a leader in sector stock research for independent investors issues a trading snapshot for natural gas stock Progress Energy Resources Corp. (TSX:PRQ), trading up at $20.07, gaining $8.52 or (73.77%) 11:04AM EDT on over 28 Million shares following news that it had entered into an agreement for the purchase by PETRONAS Canada of all of Progress' outstanding common shares at a cash price of C$20.45 per share.
Highlights
Cash price of C$20.45 per Progress share Transaction has received the unanimous approval of Progress’ Board of Directors PETRONAS brings substantial investments in LNG infrastructure and access to world markets through established channels Canadian operations to remain based in Calgary for upstream with commercial office in Vancouver for LNG
About PETRONAS
PETRONAS is the national oil and gas company of Malaysia. Incorporated in 1974 the company, ranked among the most profitable among the Fortune Global 500 entities, is engaged in the oil, gas and petrochemicals industries with strategic business assets and interests in more than 30 countries. It is one of the world’s leading LNG companies and is fully involved in every value chain of the LNG business, from liquefaction and shipping to re-gasification and trading. Apart from its Malaysian production facility, currently one of the world’s largest, PETRONAS also owns interests in LNG assets in Australia and Egypt.
About Progress Energy

Progress is a Calgary, Canada-based Energy Company focused on exploration, development and production of large, unconventional natural gas resources in northeast British Columbia and northwest Alberta . Progress holds the largest acreage position in the Montney shale gas play. Throughout its history, Progress has a solid track record of growing reserves, production and the underlying value of the Company for its shareholders. Common shares of Progress are listed on the Toronto Stock Exchange under the symbol PRQ.
Research natural gas stocks at Investorideas.com directory
Research cleantech stocks at the renewable energy stocks directory
Sign up for the free investor news and stock alerts at Investorideas.com
Join Investor Ideas - Become a Member
Investorideas.com Members currently have 24/7 online access to exclusive subscriber-only 13 stock directories in leading sectors including natural gas, renewable energy, water, biotech, nanotech and more : http://www.investorideas.com/membership/
About www.InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising.
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Investorideas.com
800 665 0411

Biotech Stock Alert; Aethlon Medical (AEMD) Note: Cancer Treatment Publication Authored by Aethlon Medical Researchers Now Available

SAN DIEGO - June 27, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.

On June 12 th, I issued a detailed note referencing a landmark discovery that cancer-secreted exosomes seed the spread of metastasis in melanoma patients, and added that the Aethlon Hemopurifier®, which we have been advancing with promising results in the treatment of hepatitis c (HCV) infected individuals, has been validated in vitro to capture a variety of cancer-secreted exosomes, including those tested from melanoma patients.
Last week, we disclosed that the U.S. Patent and Trademark Office (USPTO) provided a Notice of Allowance for U.S. Patent Application No. 12/282152 entitled "Extracorporeal Removal of Microvesicular Particles," which provides us with broad rights to remove immune suppressive microvesicular particles, which include but are not limited to exosomes, from the circulation of treated patients.
Today, I am pleased to disclose that a paper authored by members of our Aethlon team, entitled, "Exosome Removal as a Therapeutic Adjuvant in Cancer" was published this morning in the Journal of Translational Medicine and is now accessible online at www.translational-medicine.com.
We believe the publication to be quite timely as cancer-secreted exosomes have recently emerged to become a vital therapeutic target as they play an instrumental role in promoting tumor progression by inducing programmed cell death of anti-cancer immune cells. As a result of inhibiting the immune response, exosomes increase the proliferation and spread of many forms of cancer. The particles also seed the spread of tumor metastasis, promote angiogenesis (essential for tumor survival and growth), increase tumor aggressiveness, and contribute to anti-cancer drug resistance.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
All financial disclosures, anticipated revenue recognition amounts and other information related to the financial results and operations of the Company set forth above are unaudited and are subject to year-end audit adjustments and footnote disclosures.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

Pharma Stock Trading Alert: SBFM has Record Breaking Volume and 50% Gains Following News

New York, New York - June 27, 2012 (Investorideas.com newswire) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Pharma stock Sunshine Biopharma following yesterdays trading activity.
Sunshine Biopharma Inc. (OTCBB:SBFM) traded as high as $0.35, gaining 0.07 or (50.00%) yesterday on record volume of over 300,000 shares. The Company announced yesterday that it has completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro. The results of the study showed that Adva-27a is significantly more effective at killing Multidrug Resistant Small Cell Lung Cancer cells than Etoposide, the current commonly used drug for this type of cancer. This is the second form of Multidrug Resistant Cancer that Adva-27a has shown effectiveness against. The first, which we had announced on July 11, 2011, was MCF-7/MDR Multidrug Resistant Breast Cancer.
Read SBFM news: http://www.investorideas.com/news/2012/biotech/06261.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and stock alerts at Investorideas.com
Research biotech stocks at the Biotech stocks Directory and biotech news and research at www.biotechindustrystocks.com
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: SBFM compensates Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26th. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

Published at Investorideas.com newswire

Learn more about Sunshine Biopharma Inc. (OTCBB:SBFM): Profile
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensates Investorideas.com for news release publishing and distribution : one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

China Stock Investor News Alert: Ziyang Ceramics (OTCBB: ZYCI) Reports New Deals of $1.3 Million per Month

ZHUCHENG, CHINA - June 26, 2012 (Investorideas.com newswire) Ziyang Ceramics Corporation (OTCBB: ZYCI), a leading manufacturer of high quality interior porcelain tiles in China , announced today that the Company has signed 10 new distribution agreements with distributors in Shandong and Jiangsu provinces of China thus far in the second quarter of 2012. The new distribution agreements collectively call for minimum sales orders of approximately $1.3 million per month.

Under the terms of the agreements, Ziyang will provide its full line of floor and interior wall tiles to the distributors on a private label basis. The distributors will market the tiles under their own proprietary brand names. Ziyang will provide warehousing and will receive full payment for each order prior to its release from the warehouse. Ziyang received a total of approximately $160,000 from the ten distributors as a refundable cash deposit provided they meet certain minimum sales targets.
Commenting on the new distribution agreements, Mr. Lingbo Chi, CEO of Ziyang Ceramics, stated, "We are excited to continue to expand our distribution network. Our sales team has been aggressively working to add quality business partners as we increase our product offerings. By bringing on additional private label relationships we expect to continue to gain market share in the provinces we service to help further fuel our revenue growth in the second half of 2012 and beyond. We remain committed to our goal of becoming the leading manufacturer of porcelain tiles in Eastern and Central China as we look to maximize the financial performance of our company for the benefit of our stockholders."
About Ziyang Ceramics Corporation
Ziyang Ceramics Corporation, headquartered in Zhucheng city of Shandong Province in China , manufactures porcelain tiles used for interior residential and commercial applications and sells through a distribution network of more than 150 distributors across 10 provinces, concentrating on major second and third tier cities located primarily in Eastern and Central China . For more information about Ziyang Ceramics Corporation, please visit: www.ziyangcorp.com.
Safe Harbor Statement
In connection with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Ziyang Ceramics Corporation is hereby providing cautionary statements identifying important factors that could cause it's actual results to differ materially from those projected in forward-looking statements (as defined in such act). Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "intends," "plans," "believes" and "projects") may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. These statements include, but are not limited to, our expectations regarding the ability of our new distributors to meet minimum sales requirements, the expansion of our sales and distribution network and our expectations regarding new product development, market share and our position within the tile industry in China.
We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. This press release is qualified in its entirety by the cautionary statements and risk factor disclosure contained in our Securities and Exchange Commission filings, including our Annual Report on Form 10-K for the year ended December 31, 2011.
Contact:
Ziyang Ceramics Corporation
U.S. Representative
Pearl Group Advisors
Dore Perler
Tel:(954) 232-5363
Email: Dore@PearlGroupAdvisors.com

Published at Investorideas.com Newswire
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Microcap Pharma Stock Investor News Alert: SUNSHINE BIOPHARMA'S (SBFM) Adva-27a FOUND TO BE EFFECTIVE AT KILLING MULTIDRUG RESISTANT LUNG CANCER CELLS

Montreal, Quebec, Canada - June 26, 2012 (Investorideas.com Newswire) Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro. The results of the study showed that Adva-27a is significantly more effective at killing Multidrug Resistant Small Cell Lung Cancer cells than Etoposide, the current commonly used drug for this type of cancer. This is the second form of Multidrug Resistant Cancer that Adva-27a has shown effectiveness against. The first, which we had announced on July 11, 2011, was MCF-7/MDR Multidrug Resistant Breast Cancer.

"These findings are very interesting", said Dr. Steve N. Slilaty, Sunshine’s President and CEO. "Cancer cells become resistant to anti-tumour drugs by overproducing a certain type of trans-membrane proteins called ABC Transporters. These trans-membrane proteins bind and transport drugs from the intracellular milieu to the outside of cancer cells thereby making them resistant. Of the approximately 49 ABC Transporters identified to date, two are most often found in Multidrug Resistant Cancer: MDR1 and MRP1. The MCF-7/MDR Multidrug Resistant Breast Cancer cell line, which we had previously announced overproduces MDR1 while the H69AR Multidrug Resistant Lung Cancer cell line test in the present study overproduces MRP1. It is remarkable that our Adva-27a is able to overcome both of these resistance proteins", he added.
About Sunshine Biopharma Inc. (OTCBB: SBFM)
www.sunshinebiopharma.com
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Published at www.Investorideas.com Newswire
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensates Investorideas.com for news release publishing and distribution : one hundred thousand 144 shares for three months starting June 26 th. BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

Biotech and Pharma Stocks Make NASDAQ Top Percentage Gainers: ALXA, SNTA

New York, New York - June 25, 2012 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Pharma stocks making the NASDAQ top five percentage gainers in morning trading.

Alexza Pharmaceuticals Inc. (NASDAQ: ALXA) is trading at $4.52, gaining 0.55 or (13.85%) as of 11:41AM EDT on 2.5 Million shares, with a morning high of $4.99. The Company reported Friday that it has resubmitted its ADASUVE New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2012. ADASUVE is being developed for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. In the coming weeks, Alexza expects to hear from the FDA regarding the completeness of the resubmitted NDA, the classification of the resubmission (Class 1 or Class 2) and what the new Prescription Drug User Fee Act (PDUFA) goal date will be. Class 1 and Class 2 resubmissions have targeted review periods of 2 months and 6 months, respectively.
Synta Pharmaceuticals Corp. (Nasdaq: SNTA) trading at $7.88, gaining 0.64 or (8.84%) 11:38AM EDT. The stock has a morning high of $8.50 on volume of over 2. 1 Million shares.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and stock alerts at Investorideas.com
Research biotech stocks at the Biotech stocks Directory and biotech news and research at www.biotechindustrystocks.com
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

Renewable Energy Stock Trading Alert: Amyris (NASDAQ:AMRS) Gains over 12%

New York, NY - June 25, 2012 (Investorideas.com renewable energy newswire) Investorideas.com, a leader in renewable energy stock research for independent investors, issues an investor alert Amyris, Inc. (NASDAQ: AMRS), trading up at $3.66, up $0.37(11.25%) 11:18AM EDT on over 1.5 Million shares.
The stock was mentioned in TheStreet.com commentary on Friday as one of four stocks poised to break out.
About Amyris, Inc. Amyris is an integrated renewable products company focused on providing sustainable alternatives to a broad range of petroleum-sourced products. Amyris uses its industrial synthetic biology platform to convert plant sugars into a variety of hydrocarbon molecules -- flexible building blocks that can be used in a wide range of products. Amyris is developing and producing these products both as No Compromise(R) renewable ingredients in cosmetics, flavors and fragrances, polymers, lubricants and consumer products, and also as No Compromise renewable diesel and jet fuel. Amyris Brasil Ltda., a subsidiary of Amyris, oversees the establishment and expansion of Amyris's production in Brazil. Amyris also has fuel distribution capabilities in the United States through its subsidiary, Amyris Fuels, LLC. More information about Amyris is available at www.amyris.com.
Research more cleantech stocks on global stock exchanges - and up to 1400 at
Investorideas.com renewable energy stocks stock directory

About Investorideas.com - a leader in cleantech investor research
www.Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Follow Investorideas.com on Twitter
Follow Investorideas.com on Facebook
Follow Investorideas.com on Google Plus
Follow Renewable Energy Stocks on Facebook.com
Sign Up: Get Free investor news and stock alerts
Join Investor Ideas Get 24/7 Login to 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks, tech and more.
Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp Investorideas.com was not compensated for this report and does not hold a position in the stock
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information about Investorideas.com
contact:
800.665.0411

"Solar Stocks Starting to Show a Pulse" - J. Peter Lynch

New York, New York - June 22, 2012 - Solar stocks report at Investorideas.com Investorideas.com, a leader in renewable energy stock research for independent investors releases solar stocks commentary from solar expert, J Peter Lynch following some positive moves in solar stocks FSLR and CSUN today.
Solar Stocks Commentary with J Peter Lynch at Investorideas.com
http://www.investorideas.com/PL/
As I said in my article on 28 May 2012:

"It is always difficult to determine when to buy a stock or when to buy into a depressed industry sector, like our current solar sector. But when I look back in history it is sometimes informative to read some quotes by famous investors regarding situations such as this - here are three.

• "The time to buy is when there's blood in the streets." Baron Rothschild
• "I buy when other people are selling". J. Paul Getty
• "Bull markets are born on pessimism, grow on skepticism, mature on optimism, and die on euphoria". John Templeton

Today's solar market segment certainly fits ALL of these quotes - the blood is running on the streets, Everyone is selling or has sold and the mood is without question one of pessimism.
It would seem that now is the time to buy some solar stocks and see if history repeats itself - it DOES violate all of the rules I have outlined for you in all past articles, but if one wanted to take a crazy flyer this would be the time. This assumes you are aware that it is highly risky and maybe just a trade.
What I am going to do is to research all of our stocks and some of the related ETF's and come back to you, very shortly, with a list of the stocks and ETF's that I think are the strongest, technically speaking so that IF you want to take a flyer you will at least be buying the strongest technical stocks".

At that time every one of our solar stocks were BELOW their 50 day moving average and they were oversold by an average of roughly 74% and nothing positive was in sight.

Since then they have started to turn around and a number of stocks have moved ABOVE their 50 day moving average and they are also showing positive momentum both weekly and monthly. See the following table of solar stocks as of the close yesterday.
I have highlighted Five (5) stocks that I feel are the strongest of the entire group at this time:
CSIQ, CSUN, HSOL, SOL, TSL
So if you wanted to take a "crazy flyer" KNOWING FULL WELL that it is highly risky especially in light of the weak and volatile market - these would be the five stocks I would select.
Solar Stock as of the Close Thursday June 21st
Background Analysis Notes
Keep in mind that there are two basic types of equity (stock) analysis. Below are a brief description of each and its primary purpose:
Fundamental Analysis - this is the analysis of the fundamental financial condition of a company to identify which stocks you may want to buy when the timing is right. This form of analysis will give you NO indication of the best time to buy a stock or sell a stock.
Technical Analysis - this form of analysis will tell you "when" to buy a stock and when to sell the stock. It will do this by showing you (in chart format) the basic interaction of supply and demand and when the two change and shift which will indicate a time to buy or a time to sell.

Mr. Lynch has worked, for 35 years as a Wall Street security analyst, an independent security analyst and private investor in small emerging technology companies. He has been actively involved in following developments in the renewable energy sector since 1977 and is regarded as an expert in this field. He was the contributing editor for 17 years to the Photovoltaic Insider Report, an early publication in PV that was directed at industrial subscribers, such as major energy companies, utilities and governments around the world. He is currently a private investor and has from time to time been a financial/technology consultant to a number of companies. He can be reached via e-mail at: SOLARJPL@aol.com. Please visit his website for the promotion of solar energy � www.sunseries.net.

Research more solar stocks on global stock exchanges - and up to 1300 renewable energy stocks at Investorideas.com http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Investors - sign up for free green stocks trading alerts and news
http://www.investorideas.com/Resources/Newsletter.asp
Follow Renewable Energy Stocks onFacebook.com
http://www.facebook.com/renewableenergystocks
Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894 Disclaimer: The views and opinions expressed in the research published are those of the individual companies and writers and not necessarily those of Investorideas.com® or any of the industry sector portals. At the time of publication, writers may hold positions in the stocks or companies mentioned .
For more information about Investorideas.com contact:
800.665.0411

Graphite Stocks Alert: LOMIKO (TSX.V: LMR, OTC: LMRMF) RECEIVES DRILLING PERMIT FOR QUATRE MILLES GRAPHITE PROPERTY

Vancouver BC - June 22, 2012 (InvestorIdeas.com Newswire) LOMIKO METALS INC. (TSX-V:LMR, OTC: LMRMF, FSE: DH8B www.lomiko.com) (the "Company") announces that Lomiko has received a drilling permit and is preparing for the upcoming drilling at the Quatre Milles East Property.

Consul-Teck has proposed a budget of $307, 028 for Phase I and a contingent $724,041 for Phase II for work for the property in the technical report. Lomiko's drilling will focus on verifying the areas of historical high-grade graphite intersected previously by Graphicor on the property. The historical results are detailed below. It is Lomiko's goal to complete both Phase I & II and establish a flake graphite resource at the Quatre Milles Property by December 2012.
Future Markets Inc published "The World Market for Graphene" in October 2011. A summary of the Report's contents indicates:
"Graphene has moved swiftly from the research laboratory to the marketplace, driven by demand from markets where advanced materials are required. These include the aerospace, automotive, electronics, energy storage, solar, oil service, and lubricant sectors. The distinctive electronic, thermal and mechanical properties of graphene make it a potentially disruptive technology across a raft of industries. In 2010, there were over 400 patents issued on graphene and 3,000 research papers published. The European Union is funding a 10 year 1,000 million euro coordination action on graphene. South Korea is set to spend $350 million on commercialization initiatives and the United Kingdom has announced investment of £50million in a new commercialization hub."
Lomiko Metals In conjunction with Visual Capitalist has developed a Graphene Infographic for the use of investors.
Copy and Paste the following in your browser to review:
http://bit.ly/NVlg6O
Lomiko's Quatre Milles Graphite Property
The Quatre Milles Property is road accessible and is located approximately 175 km northwest of Montreal and 17 km due north of the village of Sainte-Veronique, Quebec. The property consists of 28 contiguous claims totaling approximately 1,600 hectares.
The property was originally staked and explored by Graphicor Resources Inc. ("Graphicor") in the summer of 1989 based on the results of a regional helicopter-borne EM survey. The underlying geology consists of intercalated biotite gneiss, biotite feldspar gneiss, marble, quartzite and calc-silicate lithologies of the Central Metasedimentary Belt of the Grenville Province.
Historical Highlights
Graphicor completed reconnaissance mapping and prospecting as well as ground geophysics and a 26 hole diamond drill program totaling 1,625 metres. The work identified several conductive trends in the central portion of the property and at least three, relatively flat lying graphitic beds. Three surface samples were collected and analyzed returning results of 14.16% Cgf, 18.06% Cgf and 20.35% Cgf. 23 of the initial 26 drill holes intersected graphite concentrations with graphite concentration in range of 4.69% in hole Q90-1 to a highlight of 8.07% Cgf over 28.60 metres in hole Q90-7. The highest individual assay was reported in hole Q90-10 reporting 15.48% Cgf over 0.50 metres. A table of results from the 43-101 indicates:
The Company cautions that it has not had the chance to verify the quality and accuracy of the historic sampling and drilling results reported in this news release which predate the introduction of NI 43-101 and cautions readers not to rely upon them. The historic figures were generated from sources believed to be reliable, however, they have not been confirmed. Although the sampling and drilling results are relevant, they have not been verified.
Graphite Market

• The price for flake graphite is $ 2000-$4000 per tonne depending on flake size and grade.
• Graphite prices have been increasing in recent months and over the last couple of years prices for large flake, high purity graphite (+80 mesh, 94-97%C) have more than doubled.
• Graphite prices have almost tripled since 2005 due to the ongoing industrialization of China, India and other emerging economies and resultant strong demand from traditional steel and automotive markets.
• Demand for graphite is expected to rise as electric vehicles and lithium battery technology are adopted, nuclear reactors are built in China, and if fuel cells and graphene patents become products.
• China, which produces about 70 per cent of the world's graphite, is seeing production and export growth leveling, and export taxes and a licensing system have been instituted.
• Europe and the USA have both indicated graphite is of economic importance and has a supply risk (Critical Raw Materials for the EU, July 2010).

Graphite Facts

• Natural graphite comes in several forms: flake, vein, amorphous and lump.
• Southwestern Quebec is host to some of the most favorable geological terrain for graphite exploration in Canada and is known to host graphite resources, including the nearby Lac Des Iles mine operated by Timcal.
• Graphite has many important new applications such as lithium-ion batteries, fuel cells, and nuclear and solar power that have the potential to create significant incremental demand growth.
• There is roughly 20-30 times more graphite by weight needed to produce a lithium-ion battery than there is lithium.
• Of the 1.2 million tonnes of graphite produced annually, approximately 40 per cent is of the most desirable flake type.
li> High-growth, high-value graphite applications require large-flake and high-purity graphite which is the prime exploration and development target at the Quatre Milles Property.

Near-Term Strategy
Lomiko plans to mount an aggressive exploration campaign on the Quatre Milles Graphite Property commencing with a complete compilation of historic geologic work followed by surface mapping, prospecting and follow-up diamond drilling.
Jean-Sebastien Lavallée (OGQ #773), geologist, a Qualified Person as defined by National Instrument 43-101, has reviewed and approved the technical content of this release.
For more information, review the website at www.lomiko.com , contact
A. Paul Gill at 604-729-5312 or email: info@lomiko.com
On Behalf of the Board
"A. Paul Gill"
Chief Executive Officer
We seek safe harbor. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release .
Published at Investorideas.com Newswire
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas.com was paid $500 to publish and distribute this news release. www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Let's Give them Something to Talk about in Solar Stocks: First Solar (NASDAQ:FSLR) on the Run On News of LA County Deal

New York, NY - June 22, 2012 (Investorideas.com renewable energy/green newswire) Investorideas.com news staff: Investorideas.com, a leader in renewable energy stock research for independent investors, issues a trading alert for solar stock First Solar, Inc. (NASDAQ:FSLR), currently trading at $15.85, up $ 1.31 or (9.01%) as of 10:40AM EDT on volume of 5.4 Million shares. The stock has a morning high of $16.42.
The Company reported news today that it has reached an agreement with the Los Angeles County Department of Public Works on the installation of solar modules at the Solar Ranch One photovoltaic (PV) power plant, currently under construction in the Antelope Valley.
Under the agreement, First Solar will continue construction of the 230-megawatt power plant that, when completed in 2013, will generate enough electricity to power 75,000 homes.
About First Solar, Inc. (NASDAQ:FSLR)
First Solar is a leading global provider of comprehensive photovoltaic (PV) solar systems which use its advanced thin-film modules. The company's integrated power plant solutions deliver an economically attractive alternative to fossil-fuel electricity generation today. From raw material sourcing through end-of-life module collection and recycling, First Solar's renewable energy systems protect and enhance the environment. For more information about First Solar, please visit www.firstsolar.com.

Research more solar stocks on global stock exchanges -and up to 1400 renewable energy stocks at Investorideas.com http://www.investorideas.com/ Companies/RenewableEnergy/Stock_List.asp
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com on Google Plus
Follow Renewable Energy Stocks onFacebook.com
http://www.facebook.com/renewableenergystocks
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/ Resources/Newsletter.asp
Join Investor Ideas Get 24/7 Login to 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks, tech and more. Join: http://www.investorideas.com/ membership/
Disclaimer/ Disclosure : Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information about Investorideas.com
contact:
800.665.0411

Biopharmaceutical Stock Alert: Onyx Pharmaceuticals (NASDAQ: ONXX) Big Moves on FDA Positive Vote

New York, New York - June 21, 2012 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), one of the NASDAQ’s top gainers, trading at $62.18, up $17.60 or (39.48%) as of 11:14AM EDT on over 16 Million shares. The stock has a morning high of $63.22.
The Company announced yesterday that the U.S. FDA's Oncologic Drugs Advisory Committee (ODAC) determined by a vote of 11-0 [with 1 abstention] that, in patients with relapsed and refractory multiple myeloma who have received at least two prior lines of therapy that included a proteasome inhibitor and an immunomodulatory agent (IMiD), the benefit-risk assessment is favorable for the use of Kyprolis� (proposed brand name for carfilzomib). Onyx is developing Kyprolis for use in multiple myeloma across a variety of treatment lines.
About Onyx Pharmaceuticals, Inc.
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx.com.

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/ Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/ Investorideas
Sign up for the free investor news and stock alerts at Investorideas.com
Research biotech stocks at the Biotech stocks Directory and biotech news and research at www.biotechindustrystocks.com
Become an Investorideas.com Member
http://www.investorideas.com/ membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

TSX Rare Earth Stocks Alert: Orbite Aluminae (TSX: ORT) on the Move

New York, NY - June 21, 2012 - www.InvestorIdeas.com, a leader in sector research for independent investors issues a trading alert for TSX rare earth stock, ORBITE ALUMINAE INC (TSX:ORT) trading up at $2.12, gaining 0.17 or (8.72%) as of 10:21AM EDT, with a morning high of $2.27 on over 1 Million shares.
The Company today announced that an independent analysis of samples of individual rare earth oxides (REO) and rare metal oxides (RMO) has confirmed a 23% increase in recovery rates over the figures published in the Revised Preliminary Economic Assessment Technical Report dated May 31, 2012, thereby increasing value of its smelter grade alumina (SGA) production project. Orbite also reanalyzed results of the various drilling campaigns carried out in recent years, confirming previously disclosed results.
About Orbite
Orbite currently owns 100% of the mining rights over a total of 60,984 hectares including the Grande-Vallee property measuring 6,665 hectares, the site of an aluminous clay deposit located 23 km south of Grande-Vallee, and a 2,600 m2 facility in the process of being converted into a high-purity alumina plant in Cap Chat, in the Gaspe region. An NI 43-101 report identified over 1 billion tonnes of aluminous clay in part of the deposit. The Company also owns ten different families of intellectual property rights (and patent pending), protected by Canadian and U.S. patents, for extracting alumina and for which patents are also pending in other countries.

Sign up for the free investor news and stock alerts at Investorideas.com
Research other TSX and global mining stocks with the Investorideas.com mining stocks directory - over 1500 stocks
Join Investor Ideas - Become a Member
Investorideas.com Members currently have 24/7 online access to exclusive subscriber-only 13 stock directories in leading sectors including mining and energy stocks: http://www.investorideas.com /membership/
About www.InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. No disclosure to report
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source - Investorideas.com
800-665-0411

Solar Energy Stocks Still Rising as Oil Declines: (CSUN), (FSLR), (WEST)

New York, NY - June 21, 2012 (Investorideas.com renewable energy/green newswire) Investorideas.com news staff: Investorideas.com, a leader in renewable energy stock research for independent investors, issues a trading alert for solar stocks. The sector looks like has reached a bottom recently, with several of the well-known players showing an uptrend, even as oil prices decline.

China Sunergy Co. Ltd. (NASDAQ:CSUN) is up, trading at $1.79, gaining 0.09(5.29%) 10:06AM EDT
First Solar, Inc. (NASDAQ: FSLR) is trading at $14.94, up marginally at 0.01(0.07%) 10:04AM EDT with a morning high of $15.34.
Westinghouse Solar, Inc. (NASDAQ: WEST) is trading at $0.31, up 0.02(6.90%) 10:07AM EDT
The Dow Jones is down over 21 Points and oil is down, trading at 80.760002 at the time of this report.
The sector had been beaten down so badly that a sign of strength in the global industry in select markets is moving stocks in spite of lower oil prices.
Japan's shift to solar has been a recent factor in some of the stocks turning to the upside.
A report from the Solar Future UK conference had Giovanni Terranova, founding partner of Bluefield Partners LLP, a specialist asset manager for solar PV infrastructure, stating he sees increasing opportunities in the UK market for installers and investors:
"The UK solar industry has reached an important and exciting stage in its development and has the opportunity, for the first time, to be the cornerstone of the government's onshore renewable policy.
Due to significant cost reductions in the price of modules the solar industry in the UK is now a cost-effective solution in comparison to other renewable technologies. Solar has the potential, using lower subsidies, to see to a significant increase in installed capacity over the coming years and to be a major part of the government's 2020 renewable electricity target. The 22GW target set and confirmed by the Government has the potential to transform the UK market in one of the most interesting markets in Europe over the next few years
Research more solar stocks on global stock exchanges - and up to 1400 renewable energy stocks at Investorideas.com http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com on Google Plus
Follow Renewable Energy Stocks onFacebook.com
http://www.facebook.com/renewableenergystocks
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 24/7 Login to 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks, tech and more. Join: http://www.investorideas.com/membership/
Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information about Investorideas.com
contact:
800.665.0411

Biotech Stock Breaking News: Sirona Biochem (TSX-V: SBM, OTC: SRBCF) Announces Primate Results for SGLT Inhibitor for Type 2 Diabetes

Vancouver, British Columbia - June 20, 2012 (Investorideas.com Newswire) Sirona Biochem Corp. ( TSX-V: SBM , OTC: SRBCF, Frankfurt: ZSB), announced today results from a preclinical study of its sodium glucose transporter (SGLT) inhibitor in monkeys. When administered orally, Sirona Biochem’s SGLT inhibitor, SBM-TFC-039, triggered glucosuria in a dose-dependent manner. In addition, the glucosuria effect was robust for the full 24 hours studied.

"At the recent American Diabetes Association meeting in Philadelphia, it was apparent that SGLT inhibitors are a potentially ground-breaking treatment for Type 2 diabetes," said Dr. Howard Verrico, President and CEO of Sirona Biochem. "Preclinical results of our SGLT inhibitor, SBM-TFC-039, in multiple species have consistently demonstrated its efficacy and we are exploring data that may differentiate SBM-TFC-039 from the other SGLT inhibitors in development," he added.
SBM-TFC-039 is an SGLT inhibitor drug candidate for Type 2 diabetes. In the kidneys, SGLT inhibitors reduce the reabsorption of glucose into the bloodstream by eliminating excess glucose into the urine.
SBM-TFC-039 has been tested acutely and chronically in a rodent diabetic model, in addition to the latest study in primates. In those tests, SBM-TFC-039 has consistently demonstrated a glucose-lowering effect in a dose-dependent manner.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone: 604.282.6065
Email: jjang@sironabiochem.com
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Published at the Investorideas.com Newswire
Disclaimer http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com was not compensated for this news report

Biotech Stock News Alert;Aethlon Medical (OTC: AEMD) Announces Notice of Allowance of U.S. Patent Application

SAN DIEGO - June 19, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the U.S. Patent and Trademark Office (USPTO) has given the Company a Notice of Allowance for U.S. Patent Application No. 12/282152 entitled "Extracorporeal Removal of Microvesicular Particles." The patent grants Aethlon the exclusive right to remove immune suppressive microvesicular particles, which include but are not limited to exosomes, from the circulation of treated patients. The patent describes a method to bind and capture immune suppressive microvesicular particles from blood with a medical filtration device containing single or multiple affinity agents, which can include antibodies, aptamers, beads, lectins, proteins, or other compounds that adhere to microvesicles. The USPTO further notified the Company that it has calculated a Patent Term Adjustment of 452 days on the Notice of Allowance.
"This patent allowance provides a cornerstone that reinforces our opportunity to establish a dominant market position in the therapeutic targeting of immunosuppressive exosomes," stated Jim Joyce, Chairman and CEO at Aethlon Medical. The Aethlon Hemopurifier�, which is a first-in-class device being advanced in Hepatitis C care, has demonstrated the ability to capture a broad-spectrum of immune suppressive exosomes underlying cancer. A therapy that could inhibit exosome proliferation would fulfill a major unmet medical need as corresponding drug therapies have yet to emerge.

In cancer, exosomes have recently emerged to become a vital therapeutic target as they play an instrumental role in promoting tumor progression by inducing programmed cell death of anticancer immune cells. As a result of inhibiting the immune response, exosomes increase the proliferation and spread of many forms of cancer. The particles also seed the spread of tumor metastasis, promote angiogenesis (essential for tumor survival and growth), increase tumor aggressiveness, and contribute to anti-cancer drug resistance.
Circulating microvesicles or exosomes have also been discovered to have immunosuppressive roles in infectious disease and may accelerate the pathogenesis of other disease conditions as they have been reported to induce or amplify inflammatory and pathological conditions including, cardiovascular disease, hypertension, neurodegenerative disorders, diabetes, and rheumatic diseases. Beyond its cancer and infectious disease treatment initiatives, Aethlon is studying the deleterious role of exosomes in sepsis through a contract with the Defense Advanced Research Projects Agency (DARPA).
In addition to being known as exosomes, microvesicles have been referred to as epididimosomes, argosomes, exosome-like vesicles, microparticles, promininosomes, prostasomes, dexosomes, texosomes, dex, tex, archeosomes and oncosomes.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs